This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collis, S. J. Articles by DeWeese, T. L. Search for Related Content PubMed PubMed Citation Articles by Collis, S. J. Articles by DeWeese, T. L.

Enhanced Radiation and Chemotherapy-mediated Cell Killing of Human Cancer Cells by Small Inhibitory RNA Silencing of DNA Repair Factors¹

Departments of Radiation Oncology [S. J. C., M. J. S., W. G. N., T. L. D.], Pathology [W. G. N.], and Urology [W. G. N., T. L. D.], Radiation Biology Program, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Recent developments in the use of small inhibitory RNA molecules (siRNAs) to inhibit specific protein expression have highlighted the potential use of siRNA as a therapeutic agent. The double-strand break signaling/repair proteins ATM, ATR, and DNA-dependent protein kinase catalytic subunit (DNA-PK_cs) are attractive targets to confer enhanced radio and chemosensitivity to tumor cells. We have designed and exogenously delivered plasmids encoding siRNAs targeting these critical kinases to human cancer cells to assess the feasibility of this concept as a clinically translatable experimental therapeutic. siRNA led to a 90% reduction in target protein expression. siRNAs targeting ATM and DNA-PK_cs gave rise to a dose-reduction factor of 1.4 compared with untransfected and control vector-transfected cells at the clinically relevant radiation doses. This was greater than the radiosensitivity achieved using the phosphatidylinositol 3'-kinase inhibitor Wortmannin or DNA-PK_cs competitive inhibitor LY294002. A similar increased sensitivity to the alkylating agent methyl methanesulfonate (MMS) was also observed for siRNA-mediated ATR silencing. Together, these data provide strong evidence for the potential use of siRNA as a novel radiation/chemotherapy-sensitizing agent.

This article has been cited by other articles:

				B. A. Stohr and E. H. Blackburn ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells Cancer Res., July 1, 2008; 68(13): 5309 - 5317. [Abstract] [Full Text] [PDF]

				D. Chen, Z. Yu, Z. Zhu, and C. D. Lopez E2F1 Regulates the Base Excision Repair Gene XRCC1 and Promotes DNA Repair J. Biol. Chem., May 30, 2008; 283(22): 15381 - 15389. [Abstract] [Full Text] [PDF]

				M. J. Cariveau, X. Tang, X.-L. Cui, and B. Xu Characterization of an NBS1 C-Terminal Peptide That Can Inhibit Ataxia Telangiectasia Mutated (ATM)-Mediated DNA Damage Responses and Enhance Radiosensitivity Mol. Pharmacol., August 1, 2007; 72(2): 320 - 326. [Abstract] [Full Text] [PDF]

				D. Wilsker and F. Bunz Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol. Cancer Ther., April 1, 2007; 6(4): 1406 - 1413. [Abstract] [Full Text] [PDF]

				L. Geng, K. C. Cuneo, A. Fu, T. Tu, P. W. Atadja, and D. E. Hallahan Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of {gamma}-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer Cancer Res., December 1, 2006; 66(23): 11298 - 11304. [Abstract] [Full Text] [PDF]

				M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H. P. Rodemann Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. Clin. Cancer Res., July 1, 2006; 12(13): 4119 - 4126. [Abstract] [Full Text] [PDF]

				D. Schaue and W. H. McBride Counteracting tumor radioresistance by targeting DNA repair Mol. Cancer Ther., October 1, 2005; 4(10): 1548 - 1550. [Full Text] [PDF]

				A. Munshi, J. F. Kurland, T. Nishikawa, T. Tanaka, M. L. Hobbs, S. L. Tucker, S. Ismail, C. Stevens, and R. E. Meyn Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity Clin. Cancer Res., July 1, 2005; 11(13): 4912 - 4922. [Abstract] [Full Text] [PDF]

				E. T. Shinohara, L. Geng, J. Tan, H. Chen, Y. Shir, E. Edwards, J. Halbrook, E. A. Kesicki, A. Kashishian, and D. E. Hallahan DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation-Sensitizing Drugs Cancer Res., June 15, 2005; 65(12): 4987 - 4992. [Abstract] [Full Text] [PDF]

				S. Daido, A. Yamamoto, K. Fujiwara, R. Sawaya, S. Kondo, and Y. Kondo Inhibition of the DNA-Dependent Protein Kinase Catalytic Subunit Radiosensitizes Malignant Glioma Cells by Inducing Autophagy Cancer Res., May 15, 2005; 65(10): 4368 - 4375. [Abstract] [Full Text] [PDF]

				U. K. Mukhopadhyay, A. M. Senderowicz, and G. Ferbeyre RNA Silencing of Checkpoint Regulators Sensitizes p53-Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells Cancer Res., April 1, 2005; 65(7): 2872 - 2881. [Abstract] [Full Text] [PDF]

				J. M. Atienza, R. B. Roth, C. Rosette, K. J. Smylie, S. Kammerer, J. Rehbock, J. Ekblom, and M. F. Denissenko Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 361 - 368. [Abstract] [Full Text] [PDF]

				I. Hickson, Y. Zhao, C. J. Richardson, S. J. Green, N. M. B. Martin, A. I. Orr, P. M. Reaper, S. P. Jackson, N. J. Curtin, and G. C. M. Smith Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM Cancer Res., December 15, 2004; 64(24): 9152 - 9159. [Abstract] [Full Text] [PDF]

				S. J. Collis, J. M. Schwaninger, A. J. Ntambi, T. W. Keller, W. G. Nelson, L. E. Dillehay, and T. L. DeWeese Evasion of Early Cellular Response Mechanisms following Low Level Radiation-induced DNA Damage J. Biol. Chem., November 26, 2004; 279(48): 49624 - 49632. [Abstract] [Full Text] [PDF]

				E. Willmore, S. de Caux, N. J. Sunter, M. J. Tilby, G. H. Jackson, C. A. Austin, and B. W. Durkacz A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia Blood, June 15, 2004; 103(12): 4659 - 4665. [Abstract] [Full Text] [PDF]